tbuckley/cabot-search huggingface dataset:
Advanced Glycation End Products in Children With Type 1 Diabetes: Family Matters?
Authors: Pascal Barat, Benoît Cammas, Aurélie Lacoste, Jérôme Harambat, Vanessa Vautier, Fabienne Nacka, Jean-Benoît Corcuff
Journal: Diabetes Care (2011)

Advanced glycation end product (AGE) burden can be indirectly quantified in vivo by measuring skin autofluorescence (SAF) (1). It has been recently published by Felipe et al. (2) that SAF is correlated with glycated hemoglobin (GHb) but not with mean blood glucose (MBG) in type 1 diabetic children. This suggests that factors besides MBG exposure may be influential in skin AGE generation. In the current study, we have compared SAF in type 1 diabetic children and their nondiabetic sibling.

We included 52 type 1 diabetic children, 55% boys, aged 12 (6) years [median (interquartile range: 75th percentile − 25th percentile)], and 28 nondiabetic siblings, 46% boys, aged 11 (6) years. Among diabetic children, the duration of diabetes was 71 (45) …
923-4 Predictors of Early Recovery in Left Ventricular Function After Primary Angioplasty in Acute Myocardial Infarction
Authors: Luiz A. Mattos, Fausto Feres, Luiz F. Tanajura, Ibraim Pinto, Aurea Chaves, Marinella Centemero, Gilberta Nunes, Amanda Sousa, J. Eduardo Sousa
Journal: Journal of the American College of Cardiology (1995)
A two-amino acid insertion in the Cys146- Cys167 loop of the alphaIIb subunit is associated with a variant of Glanzmann thrombasthenia. Critical role of Asp163 in ligand binding.
Authors: S Honda, Y Tomiyama, M Shiraga, S Tadokoro, J Takamatsu, H Saito, Y Kurata, Y Matsuzawa
Journal: Journal of Clinical Investigation (1998)

The ligand binding site(s) of the alpha subunit of integrin alphaIIb beta3 (GPIIb-IIIa), a prototypic non-I domain integrin, remains elusive. In this study, we have characterized a Japanese variant of Glanzmann thrombasthenia, KO, whose platelets express normal amounts of alphaIIb beta3. KO platelets failed to bind the activation-independent ligand-mimetic mAb OP-G2 and did not bind fibrinogen or the activation-dependent ligand-mimetic mAb PAC-1 following activation of alphaIIb beta3 under any condition examined. Sequence analysis of PCR fragments derived from KO platelet mRNA revealed a 6-bp insertion leading to a 2-amino-acid insertion (Arg-Thr) between residues 160 and 161 of the alphaIIb subunit. Introduction of the insertion into wild-type recombinant alphaIIb beta3 expressed in 293 cells led to the normal expression of alphaIIb beta3 having the defect in ligand binding function. The insertion is located within the small loop (Cys146-Cys167) in the third NH2-terminal repeat of the alphaIIb subunit. Alanine substitution of each of the oxygenated residues within the loop (Thr150, Ser152, Glu157, Asp159, Ser161, and Asp163) did not significantly affect expression of alphaIIbbeta3, and only Asp163AlaalphaIIb beta3 abolished the ligand binding function. In addition, Asp163AlaalphaIIb beta3 as well as KO mutant alphaIIb beta3 constitutively expressed the PMI-1 epitope. Our present data suggest that Asp163 of the alphaIIb subunit is one of the critical residues for ligand binding.
Genetic Testing for Alzheimer Disease
Authors: Kathryn Bayard Tracy
Journal: JAMA (1997)

To the Editor.  —I disagree with the conclusion drawn by Dr Post and colleagues 1 that genetic testing of asymptomatic individuals at risk for Alzheimer disease (AD) is unwarranted. Alzheimer disease is a prevalent and costly disease with tremendous attendant suffering both for the affected individual and for the family, who must bear the brunt of the inexorable decline in the individual's cognition and social skills. 2 The disease also has a protracted prodrome: it may take 30 years or longer for the brain to incur sufficient damage for clinical symptoms to manifest. But once degeneration reaches that critical point, if we follow the ethical perspective recommended in the consensus statement, we can hope only to delay or, at best, arrest the disease at the stage at which memory loss and other deficits are apparent.  From the vantage point of public health, a disease that manifests over decades offers the
The Kansas Death Statute: Bold and Innovative
Authors: Don Harper Mills
Journal: New England Journal of Medicine (1971)

By permitting their physicians to use the concept of brain death, the people of Kansas have scored a legislative precedent. Nowhere else in the common-law world do doctors have knowledge of this right prospectively, and in this age of medicolegal uncertainty, this statute stands as quite an accomplishment.Kennedy disagrees (page 946), but his criticism of the intent and nature of this law may stem from a lack of understanding of the conditions in the United States. In particular, I am impressed that he may not fully appreciate the magnitude and effects of the medical litigation dilemma we are presently . . .
Intensive training over 5 days improves colonoscopy skills long-term
Authors: S. Thomas-Gibson, P. Bassett, N. Suzuki, G. Brown, C. Williams, B. Saunders
Journal: Endoscopy (2007)

See also: Commentaire de travail de S. Thomas-Gibson et al., pp. 818Endoscopy 2007; 39(09): 932-932DOI: 10.1055/s-0032-1308871
The concern for developmental neurotoxicology: is it justified and what is being done about it?
Authors: H A Tilson
Journal: Environmental Health Perspectives (1995)

In general, it is believed that the possibility of an adverse developmental outcome following conception is relatively high. In most cases, the cause of the defect is not clear, although exposure to chemical agents at a critical period during development has been proposed to play a significant role. Consequently, regulatory agencies such as the U.S. Environmental Protection Agency (U.S. EPA) have promulgated testing guidelines for assessing developmental neurotoxicity of chemicals in animal testing protocols. Concerns have been expressed about the use of behavioral tests to evaluate chemicals for developmental neurotoxicity, since some investigators believe that they lack predictive validity for human developmental neurotoxicity. Other investigators have indicated that results from such studies are difficult to interpret because of a lack of standardization and sensitivity of the tests. Furthermore, it has been argued that the developing organism is not especially sensitive to chemicals or, if effects are observed, the developing organism is capable of compensating for the deficit. Recent research, however, has adequately demonstrated that developing organisms are especially vulnerable to chemical agents if the exposure occurs at a critical period during development, while other studies have supported the assumption that functional or behavioral effects observed in animal models can be extrapolated to humans. These findings support the routine assessment of chemicals for developmental neurotoxicity using functional end points and suggest that currently available methods could be used to determine more precisely the mechanism of chemical-induced developmental defects.
Illness behaviour in elite middle and long distance runners
Authors: A Currie, S G Potts, W Donovan, D Blackwood
Journal: British Journal of Sports Medicine (1999)

To examine the illness attitudes and beliefs known to be associated with abnormal illness behaviour (where symptoms are present in excess of objective signs and pathology) in elite middle and long distance runners, in comparison with non-athlete controls.A total of 150 athletes were surveyed using the illness behaviour questionnaire as an instrument to explore the psychological attributes associated with abnormal illness behaviour. Subjects also completed the general health questionnaire as a measure of psychiatric morbidity. A control group of 150 subjects, matched for age, sex, and social class, were surveyed using the same instruments.A multivariate analysis of illness behaviour questionnaire responses showed that the athletes' group differed significantly from the control group (Hotelling's T: Exact F = 2.68; p = 0.01). In particular, athletes were more somatically focused (difference between means -0.27; 95% confidence interval -0.50 to -0.03) and more likely to deny the impact of stresses in their life (difference between means 0.78; 95% confidence interval 0.31 to 1.25). Athletes were also higher scorers on the Whiteley Index of Hypochondriasis (difference between means 0.76; 95% confidence interval 0.04 to 1.48). There were no differences in the levels of psychiatric morbidity between the two groups.The illness attitudes and beliefs of athletes differ from those of a well matched control population. The origin of these psychological attributes is not clear but those who treat athletes need to be aware of them.
Sclerosant Extravasation as a Complication of Sclerosing Endotherapy for Bleeding Gastric Varices
Authors: H.-C. Cheng, P.-N. Cheng, Y.-M. Tsai, H.-M. Tsai, C.-Y. Chen
Journal: Endoscopy (2004)

We report here the case of a 65-year-old woman who suffered intraperitoneal sclerosant leakage after endoscopic injection sclerotherapy for bleeding gastric varices. In total, 3 ml of N-butyl-2-cyanoacrylate and Lipiodol mixture was injected. The patient developed mild fever and pain over the left upper quadrant and flank after the procedure. In addition to a Lipiodol-filled gastric varix, the imaging studies disclosed a wide spread of Lipiodol over the left peritoneal cavity. The patient was kept fasting with parenteral antibiotics and nutrition. She responded well to the treatment, and all of the symptoms had subsided 6 days later.
The Window Period Between Hepatitis B e Antigen and Antibody in Chronic Type B Hepatitis
Authors: Yun-Fan Liaw, Miau-Ju Huang, Chia-Ming Chu, I-Shyan Sheen, Deng-Yn Lin
Journal: Hepatology (1984)

To examine the period between disappearance of hepatitis B e antigen (HBeAg) and appearance of anti-HBe, 48 patients with clinicopathologically verified chronic B hepatitis were followed every 1 to 3 months after HBeAg clearance. Sera were tested by radioimmunoassay for HBeAg and anti-HBe. Anti-HBe appeared in days to years, mostly (78.7%) within 1 year, after disappearance of HBeAg. Only 40.5% of patients had an “e-window” shorter than 1 month. Clinical and histological exacerbation preceding HBeAg clearance precipitated or accelerated appearance of anti-HBe. Since the patients in the “e-window” period were positive for DNA polymerase, it is suggested that the “e-window” reflects relative insensitivity of the radioimmunoassay rather than absence of HBeAg/anti-HBe. Therefore, HBeAg can reappear and clinical activity can relapse particularly during immunosuppressive therapy.
REPORT ON LAWS REGULATING THE PRACTICE OF MEDICINE IN THE UNITED STATES AND CANADA.
Authors: RICHARD J. DUNGLISON
Journal: JAMA (1883)

[Report of a Committee read before the American Academy of Medicine at New York, October 10, 1883. The progress made in the legislative restriction of medical practice in the United States since your Committee was appointed, three years ago, to report upon the subject, has been both notable and salutary. At that time the propriety of establishing such laws was under active discussion, and weak enactments, temporizing in character and but partially effective in their action, were evoked from tardy and timorous legislators in several of the States of this country, as compromises between a sense of the necessity of doing something to protect the health of their constituents and a consciousness that the practitioners and supporters of quackery and of irregular methods of medical treatment were among the influential voters whose active opposition might jeopardize their reelection. It was also found to be impossible, in a few of the
AN INJECTABLE ACELLULAR CAPILLARY HYDROGEL IMPROVES LEFT VENTRICULAR FUNCTION AFTER MYOCARDIAL INFARCTION
Authors: Domenico G. Della Rocca, Bradley J. Willenberg, Leonardo F. Franklin, Stacy L. Porvasnik, John W. Petersen, Prateek S. Wate, Eileen M. Handberg, Gregory Schultz, Francesco Romeo, Christopher D. Batich, Barry J. Byrne, Carl J. Pepine
Journal: Journal of the American College of Cardiology (2012)
Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma
Authors: Ronnie Tung-Ping Poon, Tom Tan-To Cheung, Philip Chong-Hei Kwok, Ann-Shing Lee, Tat-Wing Li, Kwok-Loon Loke, Stephen Lam Chan, Moon-Tong Cheung, Tak-Wing Lai, Chin-Cheung Cheung, Foon-Yiu Cheung, Ching-Kong Loo, Yiu-Kuen But, Shing-Jih Hsu, Simon Chun-Ho Yu, Thomas Yau
Journal: Liver Cancer (2015)

&lt;b&gt;&lt;i&gt;Background: &lt;/i&gt;&lt;/b&gt;Hepatocellular carcinoma (HCC) is particularly prevalent in Hong Kong because of the high prevalence of chronic hepatitis B (CHB) infection; HCC is the fourth commonest cancer in men and the seventh commonest in women, and it is the third leading cause of cancer death in Hong Kong. The full spectrum of treatment modalities for HCC is available locally; however, there is currently no local consensus document detailing how these modalities should be used. &lt;b&gt;&lt;i&gt;Summary: &lt;/i&gt;&lt;/b&gt;In a series of meetings held between May and October 2013, a multidisciplinary group of Hong Kong clinicians − liver surgeons, medical oncologists, clinical oncologists, hepatologists, and interventional radiologists − convened to formulate local recommendations on HCC management. These recommendations consolidate the most current evidence pertaining to HCC treatment modalities, together with the latest thinking of practicing clinicians engaged in HCC management, and give detailed guidance on how to deploy these modalities effectively for patients in various disease stages. &lt;b&gt;&lt;i&gt;Key messages: &lt;/i&gt;&lt;/b&gt;Distinct from other regional guidelines, these recommendations provide guidance on the use of antiviral therapy to reduce the incidence of HCC in CHB patients with cirrhosis and to reduce recurrence of CHB-related HCC.
Induction of resistin-like molecule beta (RELM-beta) by respiratory allergen, IL-4, IL-13, and STAT6 in experimental asthma
Authors: C.W. DeBrosse, N. Zimmermann, N.E. King, S.M. Pope, P.C. Fulkerson, A. Mishra, M.E. Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2003)
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update
Authors: J. Douglas Rizzo, Mark R. Somerfield, Karen L. Hagerty, Jerome Seidenfeld, Julia Bohlius, Charles L. Bennett, David F. Cella, Benjamin Djulbegovic, Matthew J. Goode, Ann A. Jakubowski, Mark U. Rarick, David H. Regan, Alan E. Lichtin
Journal: Blood (2007)

To update the American Society of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epoetin. The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agents.An Update Committee ("Committee") reviewed and analyzed data published since 2002 through July 2007. MEDLINE and the Cochrane Collaboration Library databases were searched.For patients with chemotherapy-associated anemia, the Committee continues to recommend initiating an erythropoiesis-stimulating agent (ESA) as hemoglobin (Hb) approaches, or falls below, 10 g/dL, to increase Hb and decrease transfusions. ESA treatment continues to be recommended for patients with low-risk myelodysplasia for similar reasons. There is no evidence showing increased survival as a result of ESA treatment. Conclusive evidence is lacking that, absent clinical circumstances necessitating earlier treatment, initiating ESAs at Hb levels greater than 10 g/dL either spares more patients from transfusion or substantially improves their quality of life. Starting doses and dose modifications based on response or lack thereof should follow the package insert. Continuing ESAs beyond 6 to 8 weeks in the absence of response, assuming appropriate dose increase has been attempted in nonresponders as per US Food and Drug Administration-approved label, does not seem to be beneficial, and ESA therapy should be discontinued. The Committee recommends monitoring iron stores and supplementing iron intake for ESA-treated patients. ESAs should be used cautiously with chemotherapy, or in clinical states, associated with elevated risk for thromo-embolic complications. The Committee also cautions against ESA use for patients with cancer who are not receiving chemotherapy, since recent trials report increased thromboembolic risks and decreased survival under these circumstances.
Prevention of Plasma Cholesterol Elevation and Atheromatosis in the Cholesterol-Fed Bird by the Administration of Dihydrocholesterol
Authors: M. D. SIPERSTEIN, C. W. NICHOLS, I. L. CHAIKOFF
Journal: Circulation (1953)

The effect of the addition of dihydrocholesterol to a high cholesterol diet has been studied in the chicken. It is shown that in this species the elevated plasma cholesterol and resulting atherosclerosis can be reduced to normal levels by such a procedure.
Complications of Laparoscopic and Percutaneous Renal Cryoablation in a Single Tertiary Referral Center
Authors: Matvey Tsivian, Valerie H. Chen, Charles Y. Kim, Dorit E. Zilberman, Vladimir Mouraviev, Rendon C. Nelson, David M. Albala, Thomas J. Polascik
Journal: European Urology (2010)
Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda
Authors: Mar Decastro, Javier Sánchez, Jesús F. Herrera, Asunción Cháves, Rafael Durán, Luisa García-Buey, Carmelo García-Monzón, Julia Sequí, Ricardo Moreno-Otero
Journal: Hepatology (1993)

The recent identification of the hepatitis C virus and development of assays to detect antibodies to hepatitis C virus has allowed assessment of the prevalence of hepatitis C virus infection in patients with a variety of liver and other diseases. The aim of this study was to investigate the prevalence of hepatitis C virus antibodies and severity of liver injury in patients with porphyria cutanea tarda. Sixty-two patients were studied. Serum samples were analyzed for liver function parameters and markers of hepatitis B virus infection. Frozen serum samples from 34 patients with porphyria cutanea tarda, obtained when patients were seen at the hospital for the first time, were analyzed for hepatitis C virus antibodies with enzyme-linked immunosorbent assays (first- and second-generation) and a recombinant immunoblot assay. As controls, serum samples from 19,788 blood donors, 40 patients with alcoholic liver disease and 138 hospitalized patients without liver disease were also tested for hepatitis C virus antibodies. Liver biopsy was performed in 42 porphyria cutanea tarda patients. Specimens were evaluated for steatosis, siderosis, fibrosis, severity of inflammation and the presence of cirrhosis. In addition, the degree of necroinflammatory change and fibrosis were quantitated with the histologic activity index described by Knodell et al. The prevalence of hepatitis C virus antibodies in patients with porphyria cutanea tarda (62%) was higher than that in blood donors (0.79%), patients with alcoholic liver disease (17.5%) or hospitalized patients without liver disease (5.8%).(ABSTRACT TRUNCATED AT 250 WORDS)
Who is the best donor for a related HLA haplotype-mismatched transplant?
Authors: Yu Wang, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Dai-Hong Liu, Xiao-Hui Zhang, Huan Chen, Wei Han, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Yao Chen, Chen-Hua Yan, Ming-Rui Huo, Dan Li, Xiao-Jun Huang
Journal: Blood (2014)
The XYY Male
Authors: W. M. C. Brown, W. H. Price, P. A. Jacobs
Journal: BMJ (1968)

<h3>Introduction</h3> In clinical practice colonic manometry is recommended to exclude colonic inertia (no response to meal and to drug stimulation, i.e. bisacodyl) in patients with slow transit laxative-refractory constipation (Bharucha 2013). As to date, this has not been assessed by colonic HRM in adults, our <i>aim</i>was to evaluate the sensations and colonic motor response to a meal and to bisacodyl in patients with slow-transit laxative-refractory constipation. <h3>Methods</h3> Consecutive patients with slow-transit and laxative-refractory Rome III constipation were enrolled. During colonoscopy, an HRM catheter (40 sensors, 2.5 cm spaced) and an infusion tube were advanced as far as possible (caecum) and clipped to the mucosa. Colonic pressures were recorded for three hours before and two after a standardised meal, and for one hour after intra-colonic bisacodyl (10 mg). Abdominal discomfort, abdominal gas, desire to evacuate gas, desire to defecate and urgency to defecate were evaluated by means of 100 mm visual analogue scale (VAS) every 15 minutes. Number of pan-colonic pressurizations (PCPs, Corsetti 2015) and of low-amplitude (LAPSs, Dinning 2014) and high-amplitude propagating sequences (HAPSs, De Schryver 2002) were evaluated. A normal response to bisacodyl was identified by the occurrence of at least one HAPS. Data (mean±SD) were compared with those obtained in 10 healthy subjects (HS) (30±11 years, 5 females). <h3>Results</h3> A total of 24 refractory slow-transit constipation patients (43±13 years, 22 females) were studied; 15 of these also referred pain or discomfort. As compared to HS, the total number of PCPs and of LAPSs was significantly lower in patients without pain (respectively, 19±21 vs 89±40 and 6±10 vs 52±39, all p &lt; 0.01), while it did not differ in patients with pain (respectively, 60±41 and 38±46). PCPs significantly increased after a meal in HS and in patients with (p &lt; 0.01) but not in those without pain (p = 0.20). Retrograde LAPSs increased significantly after the meal in HS (p = 0.01) but not in patients, regardless of the presence of pain (all p &gt; 0.25). The response to bisacodyl was normal in all patients with pain and in 2/8 (25%) of those without pain (p = 0.01). VAS scores for discomfort differed significantly between patients with pain as compared to both patients without pain and healthy subjects (P = 0.006). <h3>Conclusion</h3> Compared to slow transit patients without pain, patients with pain have a partially preserved response to meal (increased PCPs but not LAPSs), a higher prevalence of a normal response to bisacodyl and report higher score for discomfort during manometry. <h3>Disclosure of Interest</h3> None Declared
Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia
Authors: D. Gorecka, K. Gorzelak, P. Sliwinski, M. Tobiasz, J. Zielinski
Journal: Thorax (1997)

BACKGROUND: To date only two controlled studies have been published on the effects of domiciliary oxygen treatment on survival in patients with chronic obstructive pulmonary disease (COPD) with advanced respiratory failure. The survival in such patients despite oxygen treatment remains poor. The prescription of long term oxygen therapy (LTOT) in less severe disease remains controversial. The aim of this study was to evaluate the rationale for prescribing oxygen to patients with COPD with moderate hypoxaemia. METHODS: One hundred and thirty five patients with COPD, with PaO2 7.4-8.7 kPa (56-65 mmHg) and advanced airflow limitation (mean (SD) forced expiratory volume in one second (FEV1) 0.83 (0.28) 1), were randomly allocated to a control (n = 67) and LTOT (n = 68) group. The patients were followed every three months for at least three years or until death. RESULTS: The cumulative survival rate was 88% at one year, 77% at two years, and 66% at three years. No significant differences were found in survival rates between patients treated with LTOT and controls, nor did longer oxygen use (over 15 hours per day) improve survival. Younger age, better spirometric values, and higher body mass index predicted better survival. CONCLUSIONS: Domiciliary oxygen treatment does not prolong survival in patients with COPD with moderate hypoxaemia. Airway limitation seems to determine survival in this group of patients.